Thermo Fisher (NYSE:TMO): A classic blue-chip health stock for the rest of the 2020s

Nick Sundich Nick Sundich, October 23, 2023

Capped at over US$180bn, Thermo Fisher (NYSE:TMO) is a classic blue-chip healthcare stock. It has not escaped an impact from the Biotech Bear market, but we think is primed to bounce back. Because investors don’t seem to understand that Ozempic could be an asset rather than a liability to this company.


Introduction to Thermo Fisher (NYSE:TMO)

This company is a world leading health company. You name something to do with healthcare and it is more likelier than not that Thermo Fisher does that. It makes, supplies and provides lab equipment, pharmaceutical drugs, consumables for medical devices and medical software just to name a few. This was the company that introduced single-use bio-reactors and the first automated DNA analyser.

Its mission is to ‘Enable our customers to make the world healthier, cleaner and safer’. The company began in 1956 as Thermo Electron and had a modest few decades, generating US$2bn in revenue in 2004. But it went to the next level after merging with Fisher Scientific in 2006 and now makes over US$40bn a year. The merged company has continued to grow through the popularity of its existing devices and several acquisitions made in the last decade.

Thermo Fisher is headquartered in the outskirts of Boston, Massachusetts – specifically in Waltham, a classic industrial city that was the original home of the Boston Manufacturing company. You’ll find its Australian headquarters in the Sydney suburb of Macquarie Park. We know the life sciences industry is resilient and has long-term growth prospects. It has 125,000 employees of which 7,300 are dedicated to R&D – a unit that invests $1.5bn annually.


Why you’d consider investing in it?

As is the case with many other Wall Street stocks it is because of its track record of growth and its future prospects. In the past decade, the company has delivered 14% CAGR revenue, 17% CAGR EPS and 15% for FCF.

Thermo Fisher’s potential market size has tripled in 10 years from $80bn to $240bn, all because of all the acquisitions it has made. Among them, genetic tester Life Technologies, contract manufacturer Pantheon, and clinical research services provider PPD. These 3 cost just over $37bn between them.


Thermo Fisher (NYSE:TMO) share price chart, log scale (Source: TradingView)


In the long term, Thermo Fisher is targeting 7-9% long-term revenue growth targeted and 60-75% of capital anticipated to be deployed to M&A. Thermo Fisher has a solid ESG element, not just because it is a healthcare company but because of its emission reduction efforts. It has cut Scope 1 & 2 emissions by 25% and aims for Net Zero by 2050.


Short-term difficulties but the long-term story is still in tact

Thermo Fisher is in far from a perfect state right now. After a unprecedented bull run in the life sciences industry, it is seeing more cautious spending by its clients – particularly in China. It is also suffering from bearish investor sentiment towards biotech companies due to equity market conditions generally as well as concern over the impact of weight-loss drugs Wegovy and Ozempic. Reduce obesity and you may well reduce the incidence of health problems that make many health companies money.

But these drugs may actually be a good thing for Thermo Fisher. Back in August, it was hired as a contract manufacturer by Novo Nordisk for Wegovy. Demand for the drug is causing the need for more manufacturers to be signed up, to keep up with demand. The company is nonetheless responding to short-term condition with over $450m in cost reductions

Consensus estimates for 2023 suggest US$43.7bn in revenue (down 3%) and $16.47 in EPS (down 7%). But in 2024, $46.1bn in revenue (up 5%) and $19.70 EPS (up 20%), followed by $49.6bn revenue (up 8%) and $23.33 EPS (up 18%).


A chance to grab a bargain?

The mean target price among the 24 analysts who cover the stock is $612.59, a 26% premium to the current share price. And this represents 19.8x P/E for 2024 and 17.5x for CY25. Our DCF valuation of the company, using consensus estimates and a WACC of 7.7% is US$631.32 per share, a 30% premium to the current price.

One thing to note is that although the company is a dividend payer, it is a bigger fan of share buybacks, spending $5bn in the last 2 years while less than $900m on dividends. So income investors should look elsewhere. Nonetheless, growth-oriented investors wanting the chance to buy a great company at a low price have a great opportunity here.


What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips on the top ASX stocks


Recent Posts

buy nvidia shares in australia

Should you buy Nvidia shares in Australia?

Many investors are likely wondering if they should buy Nvidia shares in Australia? Others still might be wondering just who…


Mesoblast (ASX:MSB): Will it thrive or just survive in 2024?

Mesoblast’s (ASX:MSB) struggle with regenerative medicine in 2023 involved kеy financial movеs as wеll as opеrational rеstructurings. Thе entity which…

Star Entertainment Group … the house doesn’t always win

Thе recently released 2023 annual rеport of Star Entertainment Group portrays an intricatе fiscal position featuring extensive debt rеduction, but…